Advertisement

Journal of NeuroVirology

, Volume 23, Issue 4, pp 603–614 | Cite as

Novel nanoformulation to mitigate co-effects of drugs of abuse and HIV-1 infection: towards the treatment of NeuroAIDS

  • Rahul Dev JayantEmail author
  • Venkata S. R. Atluri
  • Sneham Tiwari
  • Sudheesh Pilakka-Kanthikeel
  • Ajeet Kaushik
  • Adriana Yndart
  • Madhavan NairEmail author
Article

Abstract

Drug abuse (e.g., methamphetamine—Meth or cocaine—Coc) is one of the major risk factors for becoming infected with HIV-1, and studies show that in combination, drug abuse and HIV-1 lead to significantly greater damage to CNS. To overcome these issues, we have developed a novel nanoformulation (NF) for drug-abusing population infected with HIV-1. In this work, a novel approach was developed for the co-encapsulation of Nelfinavir (Nel) and Rimcazole (Rico) using layer-by-layer (LbL) assembled magnetic nanoformulation for the cure of neuroAIDS. Developed NF was evaluated for blood-brain barrier (BBB) transmigration, cell uptake, cytotoxicity and efficacy (p24 assay) in HIV-1 infected primary astrocyte (HA) in presence or absence of Coc and Meth. Developed magnetic nanoformulation (NF) fabricated using the LbL approach exhibited higher amounts of drug loading (Nel and Rico) with 100% release of both the therapeutic agents in a sustained manner for 8 days. NF efficacy studies indicated a dose-dependent decrease in p24 levels in HIV-1-infected HA (~55%) compared to Coc + Meth treated (~50%). The results showed that Rico significantly subdued the effect of drugs of abuse on HIV infectivity. NF successfully transmigrated (38.8 ± 6.5%) across in vitro BBB model on the application of an external magnetic field and showed >90% of cell viability with efficient cell uptake. In conclusion, our proof of concept study revealed that sustained and concurrent release of sigma σ1 antagonist and anti-HIV drug from the developed novel sustained release NF can overcome the exacerbated effects of drugs of abuse in HIV infection and may solve the issue of medication adherence in the drug-abusing HIV-1 infected population.

Keywords

NeuroAIDS Drugs of abuse Magnetic nanoparticle Sustain release formulation Blood-brain-barrier (BBB) 

Notes

Acknowledgements

We would like to acknowledge the financial support from NIH grant nos. R01-DA040537, R01-DA037838, R01-DA042706, for (MN). We also like to acknowledge NIH-AIDS Research Program for the ARV drug and HIV-1 virus. The authors also would like to acknowledge Roozbeh Nikkhah-Moshaie and the facility support of the Advanced Materials Engineering Research Institute (AMERI), FIU.

Author contributions

RDJ conducted all of the key measurements including NF preparation, characterization, in vitro drug release, BBB, and efficacy studies. VA helped in designing dose optimization, cellular uptake, cell culture studies, and p24 assays. AY and SPK helped with flow cytometer analysis. AK and ST helped with TEM, DLS, and MTT cytotoxicity studies. MN supervised the whole project.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. Ances BM, Clifford DB (2008) HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep 8:455–461CrossRefPubMedPubMedCentralGoogle Scholar
  2. Atluri VS, Kanthikeel SP, Reddy PV, Yndart A, Nair MP (2013) Human synaptic plasticity gene expression profile and dendritic spine density changes in HIV-infected human CNS cells: role in HIV-associated neurocognitive disorders (HAND). PLoS One 8:e61399CrossRefPubMedPubMedCentralGoogle Scholar
  3. Atluri VSR, Hidalgo M, Samikkannu T, Kurapati KRV, Jayant RD, Sagar V, Nair MP (2015) Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update. Front Cell Neurosci 9:212. doi: 10.3389/fncel.2015.00212
  4. Atluri VSR, Jayant RD, Pilakka-Kanthikeel S, Garcia G, Samikkannu T, Yndart A, Kaushik A, Nair M (2016) Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection. Int J Nanomedicine 11:4287CrossRefPubMedPubMedCentralGoogle Scholar
  5. Binford MC, Kahana SY, Altice FL (2012) A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Current HIV/AIDS Reports 9:287–312CrossRefPubMedGoogle Scholar
  6. Bing EG, Burnam M, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M (2001) Psychiatric disorders and drug use among human immunodeficiency virus infected adults in the united states. Arch gen Psychiatry 58:721–728CrossRefPubMedGoogle Scholar
  7. Borgmann K, Ghorpade A (2015) HIV-1, methamphetamine and astrocytes at neuroinflammatory crossroads. Front Microbiol 6:1143. doi: 10.3389/fmicb.2015.01143
  8. Buch S, Yao H, Guo M, Mori T, Mathias-Costa B, Singh V, Seth P, Wang J, Su T-P (2012) Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms. Curr HIV res 10:425CrossRefPubMedPubMedCentralGoogle Scholar
  9. Ciccarone D (2011) Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care 38:41–58CrossRefPubMedPubMedCentralGoogle Scholar
  10. Conigliaro J, Madenwald T, Bryant K, Braithwaite S, Gordon A, Fultz SL, Maisto S, Samet J, Kraemer K, Cook R, Day N, Roach D, Richey S, Justice A (2004) The veterans aging cohort study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus–infected veterans. Alcohol Clin Exp res 28:313–321CrossRefPubMedGoogle Scholar
  11. Decher G (1997) Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 277:1232–1237CrossRefGoogle Scholar
  12. Díaz L, Martínez-Bonet M, Sánchez J, Fernández-Pineda A, Jiménez JL, Muñoz E, Moreno S, Álvarez S, Muñoz-Fernández MÁ (2015) Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism. Scientific Reports 5:12442. doi: 10.1038/srep12442
  13. Ding H, Sagar V, Agudelo M, Pilakka-Kanthikeel S, Atluri VSR, Raymond A, Samikkannu T, Nair MP (2014) Enhanced blood–brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology 25:055101CrossRefPubMedPubMedCentralGoogle Scholar
  14. Durvasula R, Miller TR (2014) Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. Behav med 40:43–52CrossRefPubMedPubMedCentralGoogle Scholar
  15. Ferris MJ, Mactutus CF, Booze RM (2008) Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav rev 32:883–909CrossRefPubMedPubMedCentralGoogle Scholar
  16. Gannon BM, Reichard EE, Fantegrossi WE (2014) Psychostimulant abuse and HIV infection: cocaine, methamphetamine, and ‘bath salts’ cathinone analogs. Curr Addict Rep 1:237–242CrossRefPubMedPubMedCentralGoogle Scholar
  17. Hammond PT (2012) Polyelectrolyte multilayered nanoparticles: using nanolayers for controlled and targeted systemic release. Nanomedicine 7:619–622CrossRefPubMedGoogle Scholar
  18. Ingersoll KS, Cohen J (2008) The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav med 31:213–224CrossRefPubMedPubMedCentralGoogle Scholar
  19. Jayant RD, Madhavan N (2016) Materials and methods for sustained release of active compounds. In: US Patent App. 15/082,611Google Scholar
  20. Jayant R, Nair M (2016) Nanotechnology for the treatment of NeuroAIDS. J Nanomedicine Res 3:00047CrossRefGoogle Scholar
  21. Jayant R, Srivastava R (2007) Dexamethasone release from uniform sized nanoengineered alginate microspheres. J Biomed Nanotechnol 3:245–253CrossRefGoogle Scholar
  22. Jayant R, McShane M, Srivastava R (2009) Polyelectrolyte-coated alginate microspheres as drug delivery carriers for dexamethasone release. Drug Delivery 16:331–340CrossRefPubMedPubMedCentralGoogle Scholar
  23. Jayant RD, McShane MJ, Srivastava R (2011) In vitro and in vivo evaluation of anti-inflammatory agents using nanoengineered alginate carriers: towards localized implant inflammation suppression. Int J Pharm 403:268–275CrossRefPubMedGoogle Scholar
  24. Jayant RD, Atluri VS, Agudelo M, Sagar V, Kaushik A, Nair M (2015) Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomedicine 10:1077CrossRefPubMedPubMedCentralGoogle Scholar
  25. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ (2010) Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 16:101–114CrossRefPubMedGoogle Scholar
  26. Kaushik A, Jayant RD, Sagar V, Nair M (2014) The potential of magneto-electric nanocarriers for drug delivery. Expert Opin Drug Deliv 11:1635–1646CrossRefPubMedPubMedCentralGoogle Scholar
  27. Kaushik A, Jayant RD, Nikkhah-Moshaie R, Bhardwaj V, Roy U, Huang Z, Ruiz A, Yndart A, Atluri V, El-Hage N (2016a) Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep 6:25309. doi: 10.1038/srep25309
  28. Kaushik A, Vabbina PK, Atluri V, Shah P, Vashist A, Jayant RD, Yandart A, Nair M (2016b) Electrochemical monitoring-on-chip (E-MoC) of HIV-infection in presence of cocaine and therapeutics. Biosens Bioelectron 86:426–431CrossRefPubMedPubMedCentralGoogle Scholar
  29. Kaushik A, Jayant RD, Nair M (2016c) Advancements in nano-enabled therapeutics for neuroHIv management. Int J Nanomedicine 11:4317CrossRefPubMedPubMedCentralGoogle Scholar
  30. Kelley JL, Petry NM (2000) HIV risk behaviors in male substance abusers with and without antisocial personality disorder. J Subst Abus Treat 19:59–66CrossRefGoogle Scholar
  31. Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL (2010) HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J NeuroImmune Pharmacol 5:294–309CrossRefPubMedPubMedCentralGoogle Scholar
  32. Lucas GM, Cheever LW, Chaisson RE, Moore RD (2001) Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 27:251–259CrossRefPubMedGoogle Scholar
  33. Masson CL, Sorensen JL, Phibbs CS, Okin RL (2004) Predictors of medical service utilization among individuals with co-occurring HIV infection and substance abuse disorders. AIDS Care 16:744–755CrossRefPubMedGoogle Scholar
  34. Maurice T, Su T-P (2009) The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195–206CrossRefPubMedPubMedCentralGoogle Scholar
  35. Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S (2013) Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun 4:1707CrossRefPubMedGoogle Scholar
  36. Nair M, Jayant RD, Kaushik A, Sagar V (2016) Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv rev 103:202–217CrossRefPubMedPubMedCentralGoogle Scholar
  37. Narayanan S, Mesangeau C, Poupaert JH, McCurdy CR (2011) Sigma receptors and cocaine abuse. Curr top med Chem 11:1128–1150CrossRefPubMedGoogle Scholar
  38. Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M (1997) A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol 158:3499–3510PubMedGoogle Scholar
  39. Rabkin J, McElhiney M, Ferrando S (2004) Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. Aids 18:43–48CrossRefGoogle Scholar
  40. Ramesh G, MacLean AG, Philipp MT (2013) Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediat Inflamm 2013:480739. doi: 10.1155/2013/480739
  41. Ramirez SH, Potula R, Fan S, Eidem T, Papugani A, Reichenbach N, Dykstra H, Weksler BB, Romero IA, Couraud PO (2009) Methamphetamine disrupts blood–brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 29:1933–1945CrossRefPubMedPubMedCentralGoogle Scholar
  42. Saiyed ZM, Gandhi NH, Nair MP (2009) AZT 5′-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J Neurovirol 15:343–347CrossRefPubMedGoogle Scholar
  43. Samikkannu T, SR Atluri V, Arias AY, VK Rao K, Mulet CT, Jayant RD, PN Nair M (2014) HIV-1 subtypes B and C tat differentially impact synaptic plasticity expression and implicates HIV-associated neurocognitive disorders. Curr HIV res 12:397–405CrossRefPubMedPubMedCentralGoogle Scholar
  44. Stoops WW, Rush CR (2013) Agonist replacement for stimulant dependence: a review of clinical research. Curr Pharm des 19:7026CrossRefPubMedPubMedCentralGoogle Scholar
  45. Tomitaka A, Arami H, Raymond A, Yndart A, Kaushik A, Jayant RD, Takemura Y, Cai Y, Toborek M, Nair M (2017) Development of magneto-plasmonic nanoparticles for multimodal image-guided therapy to the brain. Nano 9:764–773Google Scholar
  46. Zhang Y, Shi Y, Qiao L, Sun Y, Ding W, Zhang H, Li N, Chen D (2012) Sigma-1 receptor agonists provide neuroprotection against gp120 via a change in bcl-2 expression in mouse neuronal cultures. Brain res 1431:13–22CrossRefPubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2017

Authors and Affiliations

  1. 1.Center for Personalized Nanomedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Herbert Wertheim College of MedicineFlorida International UniversityMiamiUSA

Personalised recommendations